Overview
- Results presented at the San Antonio Breast Cancer Symposium showed stronger risk ranking in HR-positive, HER2-negative, node-negative disease, including late recurrence beyond five years.
- In cross-validation on 2,806 cases, the ICM+ model posted a C-index of 0.705 for 15-year distant recurrence and 0.656 for late recurrence versus 0.617 and 0.518 with Oncotype DX.
- In a 1,621-patient holdout set, ICM+ achieved a C-index of 0.733 for overall recurrence and 0.705 for late distant recurrence compared with 0.631 and 0.527 for Oncotype DX.
- Investigators described potential deployment through digital pathology workflows, with slide scans or smartphone images uploaded for centralized analysis.
- The study did not evaluate prediction of chemotherapy benefit or extended endocrine therapy benefit, and the authors called for further validation, clinical-utility studies, and regulatory review before clinical use.